Literature DB >> 14531042

Role of dopamine transporter imaging in the diagnosis of atypical tremor disorders.

Vicky Marshall1, Donald G Grosset.   

Abstract

Dopamine transporter (DAT) imaging detects presynaptic dopamine neuronal dysfunction and thereby assists differentiation of conditions with and without dopamine deficit. In atypical tremor disorders, DAT imaging can differentiate between Parkinson's disease (PD), where dopamine deficit is demonstrated on DAT imaging, and essential tremor, where no dopamine deficit is found. DAT imaging may be particularly informative in monosymptomatic rest tremors, benign tremulous Parkinson's syndrome, and in the elderly in whom essential tremor may be accompanied by pseudoparkinsonism. Copyright 2003 Movement Disorder Society

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14531042     DOI: 10.1002/mds.10574

Source DB:  PubMed          Journal:  Mov Disord        ISSN: 0885-3185            Impact factor:   10.338


  13 in total

1.  Nigral Tau pathology and striatal amyloid-β deposition does not correlate with striatal dopamine deficit in Alzheimer's disease.

Authors:  Tabea H Schauer; Maximilian Lochner; Gabor G Kovacs
Journal:  J Neural Transm (Vienna)       Date:  2012-06-05       Impact factor: 3.575

2.  Use of a single [123I]-FP-CIT SPECT to predict the severity of clinical symptoms of Parkinson disease.

Authors:  Ruth Djaldetti; Therese A Treves; Ilan Ziv; Eldad Melamed; Yair Lampl; Mordechai Lorberboym
Journal:  Neurol Sci       Date:  2009-06-05       Impact factor: 3.307

3.  Reproducibility of [123I]PE2I binding to dopamine transporters with SPECT.

Authors:  Morten Ziebell; Gerda Thomsen; Gitte M Knudsen; Robin de Nijs; Claus Svarer; Aase Wagner; Lars H Pinborg
Journal:  Eur J Nucl Med Mol Imaging       Date:  2006-07-29       Impact factor: 9.236

4.  European multicentre database of healthy controls for [123I]FP-CIT SPECT (ENC-DAT): age-related effects, gender differences and evaluation of different methods of analysis.

Authors:  Andrea Varrone; John C Dickson; Livia Tossici-Bolt; Terez Sera; Susanne Asenbaum; Jan Booij; Ozlem L Kapucu; Andreas Kluge; Gitte M Knudsen; Pierre Malick Koulibaly; Flavio Nobili; Marco Pagani; Osama Sabri; Thierry Vander Borght; Koen Van Laere; Klaus Tatsch
Journal:  Eur J Nucl Med Mol Imaging       Date:  2012-11-16       Impact factor: 9.236

5.  The role of 123I-FP-CIT-SPECT in the differential diagnosis of Parkinson and tremor syndromes: a critical assessment of 125 cases.

Authors:  Friederike Sixel-Döring; Knut Liepe; Brit Mollenhauer; Ellen Trautmann; Claudia Trenkwalder
Journal:  J Neurol       Date:  2011-05-06       Impact factor: 4.849

6.  Essential tremor is not a neurodegenerative disease.

Authors:  Ali H Rajput; Charles H Adler; Holly A Shill; Alex Rajput
Journal:  Neurodegener Dis Manag       Date:  2012-06

7.  Possible impact of dopamine SPECT on decision-making for drug treatment in Parkinsonian syndrome.

Authors:  S Hesse; C Oehlwein; H Barthel; J Schwarz; D Polster; A Wagner; O Sabri
Journal:  J Neural Transm (Vienna)       Date:  2006-02-06       Impact factor: 3.575

8.  Large-scale prediction and testing of drug activity on side-effect targets.

Authors:  Eugen Lounkine; Michael J Keiser; Steven Whitebread; Dmitri Mikhailov; Jacques Hamon; Jeremy L Jenkins; Paul Lavan; Eckhard Weber; Allison K Doak; Serge Côté; Brian K Shoichet; Laszlo Urban
Journal:  Nature       Date:  2012-06-10       Impact factor: 49.962

9.  Rest Tremor Pattern Predicts DaTscan (123 I-Ioflupane) Result in Tremulous Disorders.

Authors:  Andrea Quattrone; Rita Nisticò; Maurizio Morelli; Gennarina Arabia; Marianna Crasà; Basilio Vescio; Alessandro Mechelli; Giuseppe L Cascini; Aldo Quattrone
Journal:  Mov Disord       Date:  2021-09-28       Impact factor: 9.698

10.  Difficult diagnoses in hyperkinetic disorders - a focused review.

Authors:  Francisco Cardoso
Journal:  Front Neurol       Date:  2012-10-29       Impact factor: 4.003

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.